NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free KTTA Stock Alerts $6.92 0.00 (0.00%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$6.92▼$6.9250-Day Range$6.70▼$8.7552-Week Range$5.25▼$17.40Volume358 shsAverage Volume2,347 shsMarket Capitalization$7.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Pasithea Therapeutics alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Pasithea Therapeutics Stock (NASDAQ:KTTA)Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More KTTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTTA Stock News HeadlinesApril 29, 2024 | globenewswire.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…February 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004January 8, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 2, 2024 | msn.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | markets.businessinsider.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | seekingalpha.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…January 2, 2024 | finance.yahoo.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 1, 2024 | benzinga.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesDecember 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 19, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 13, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 11, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | markets.businessinsider.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | msn.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | investorplace.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | msn.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | markets.businessinsider.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 1, 2023 | finance.yahoo.comPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionSee More Headlines Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.04% Return on Assets-45.29% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$20,000.00 Price / Sales359.84 Cash FlowN/A Price / Cash FlowN/A Book Value$22.46 per share Price / Book0.31Miscellaneous Outstanding Shares1,040,000Free Float895,000Market Cap$7.20 million OptionableNot Optionable Beta0.86 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder, MD & Executive Chairman Comp: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Comp: $480kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Comp: $345.94kDr. Graeme Currie Ph.D. (Age 57)Chief Development Officer Comp: $346.62kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics Key CompetitorsAyala PharmaceuticalsNASDAQ:ADXSVaccinexNASDAQ:VCNXCan-Fite BioPharmaNYSE:CANFTrevenaNASDAQ:TRVNCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInsidersLawrence SteinmanBought 1,500 shares on 6/2/2023Total: $12,900.00 ($8.60/share)View All Insider Transactions KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed in 2024? Pasithea Therapeutics' stock was trading at $7.40 at the start of the year. Since then, KTTA stock has decreased by 6.5% and is now trading at $6.92. View the best growth stocks for 2024 here. When is Pasithea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our KTTA earnings forecast. When did Pasithea Therapeutics' stock split? Shares of Pasithea Therapeutics reverse split on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTTA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.